Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 16/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8163366 | 0.92 | GRIA2 (0.71) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1424279 | 0.85 | GRIA2 (0.71) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1423823 | 0.85 | GRIA2 (0.74) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1424041 | 0.85 | GRIA2 (0.62) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL3136897 | 0.85 | GRIA2 (0.83) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL8170149 | 0.82 | GRIA2 (0.71) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1424092 | 0.80 | GRIA2 (0.55) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1424200 | 0.79 | GRIA2 (0.54) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1423917 | 0.78 | GRIA2 (0.58) | GRIA2CYP2C9CYP2D6CYP1A2GAA | |
| SCHEMBL1423753 | 0.78 | GRIA2 (0.51) | GRIA2CYP2C9CYP2D6CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110566-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |